We report the use of intravenous procainamide infusion in the treatment of fifteen patients with acute atrial fibrillation. Procainamide was infused at 50 mg/min to a maximum of 20 mg/kg, with blood pressure and electrocardiographic monitoring. Ten patients responded, with a mean dose of 8.7 (standard deviation 4.3) mg/kg, four of these reverting to sinus rhythm after a low dose of less than 5.0 mg/kg. Hypotension was a common concomitant and was seen in four cases, but required termination of the infusion only in a patient with cardiomyopathy. An increase in ventricular rate or conversion to atrial flutter was not seen. Intravenous infusion of procainamide is a safe and moderately effective method of cardioversion in acute atrial fibrillation.
may have been because of a high incidence of reported side-effects using dosages which would now be regarded as excessive. The efficacy of procainamide in reverting atrial fibrillation is related to the duration of fibrillation 3 ,4 or to left atrial diameter. 5 A conservative regime of procainamide infusion has recently been shown to be effective in acute atrial fibrillation,5 with little in the way of sideeffects. This paper reports experience using a regime based on that of Halpern. 5 PATIENTS AND METHODS Fifteen patients, seven males and eight females, aged 39 to 79 (mean 62.9) years were studied.
The indication for treatment was atrial fibrillation of recent onset. In each case this was less than four hours before presentation, although our protocol permitted treatment of patients with the onset of atrial fibrillation within 24 hours. No patient was taking digoxin, theophylline, or any other cardiotonic drug. No subject had evidence of severe cardiac insufficiency, hypotension, or heart block. All subjects had normal thyroid function.
The diagnosis was confirmed using a 12-lead standard electrocardiograph. The patient's rhythm was continuously monitored during infusion and for 12 hours afterwards. Cuff blood pressure was determined at five-minute intervals during the infusion and until stabilised.
Procainamide was given as a loading dose to a maximum of 20 mg/kg. It was dissolved in a 5070 dextrose solution and infused at a rate of 50 mg/min by infusion pump (IVAC). The indications for stopping infusion were: 1. m~ximum dose (20 mg/kg) attained without reversion to sinus rhythm, 2. hypotension with a greater than 20% fall in systolic blood pressure, 3. QRS widening> 130% of normal, or 4. 2nd or 3rd degree AV block.
In patients whose atrial fibrillation was converted to sinus rhythm the procainamide infusion was continued at 2-4 fig per minute for 24 hours and was then stopped. On-going anti-arrhythmic therapy was not employed.
RESULTS
Ten patients converted to sinus rhythm and five did not (Tables lA and 1B ). Those whose rhythm was converted to sinus rhythm remained in that rhythm for the duration of their hospital admission. Three of the five non-convertors had full dosages without ill-effect, and in two the infusion had to be stopped according to protocol. The mean dosage of procainamide in the convertors was 8.7 (standard deviation 4.3) mg/kg, and in the non-convertors was 16.4 (5.1) mg/kg. The most common diagnosis was ischaemic heart disease. Five patients had had acute myocardial infarction, and, of these, four reverted to sinus rhythm. In two cases, the arrhythmia was idiopathic (cases 1 and 14) but all other subjects had co-existing diseases which might predispose them to the dysrhythmia. Two patients were quite ill (cases 5 and 7), one with septicaemia associated with Crohn's disease and cerebral oedema, and the other with sepsis and acute renal failure following multiple trauma. The infusion was tolerated and was effective in both instances.
The most common side-effect was hypotension. In three subjects, the systolic blood pressure fell by 20 mmHg, and in one, a case of viral cardiomyopathy, it fell to 70 mmHg. This responded to simple postural manoeuvres and cessation of the infusion.
Aberrant conduction was seen in two patients, with rate-related intermittent widening of the QRS complex. This was transient in one case, but lasted for a minute in the second, before the infusion was terminated.
One subject developed vaso-vagal syncope 10 minutes after reversion, when sat up for an electrocardiogram.
No acceleration of ventricular rate, reversion to atrial flutter, or heart block was observed. DISCUSSION We found intravenous procainamide, used according to our protocol, moderately effective in restoring acute atrial fibrillation to sinus rhythm in 10 of our 15 patients. In only two cases was the infusion stopped because of sideeffects. Hypotension was common, occurring on four occasions, and was sufficient to cause alarm in one patient.
Procainamide is a class 1 anti-arrhythmic drug. Its principal action is to decrease automaticity and conduction velocity, and to increase action potential duration and refractory period by a decrease in membrane responsiveness. 6 It may increase heart rate because of vagal block,7 but may have sideeffects related to delayed conduction, including AV block and QRS prolongation.
Hypotension was a common and serious concomitant of procainamide use in earlier studies. 3 ,4,8 It is related to the rate of infusion of drug, and is less likely to occur at infusion rates between 25 and 50 mg/min,7,9 which allow adequate distribution of procainamide. It is due mainly to peripheral but also to cardiac effects. 7 QRS widening, conversion to flutter, and an increased heart rate were also frequently reported in series that used high dosage schedules. 3 ,4,to In the more conservative regime Our protocol is based on that of Halpern,5 although we have used a slightly higher rate of infusion of procainamide (50 mg/min compared with 30 mg/min). This rate of infusion is within the generally recommended range. 7 ,9 We were unable to measure plasma levels of procainamide.
In contrast to Halpern's series where reversion to sinus rhythm was not achieved below 10 mg/kg,5 four of our ten convertors did so at extremely low dosages (5.0 mg/kg or less). The mean dosage required in the convertors, 8.7 (SO 4.3) mg/kg, was lower than that in Halpern's patients, 13.3 (SO 3.6) mg/kg. 5 This may be attributed to the acute onset of fibrillation in our patients and the selection of subjects without valvular heart disease or cardiac failure of a degree to cause atrial dilatation.
The regime was used on five cases with acute myocardial infarction, one of whom became mildly hypotensive. The apparent tolerance of procainamide by these patients is in keeping with its widespread acceptance for the treatment of ventricular arrhythmias in acute infarction. The degree of hypotension in the one patient with cardiomyopathy suggests that the drug might be avoided in similar circumstances.
It should be realised that acute atrial fibrillation may revert spontaneously to sinus rhythm, but the uncertainty of this assumption in the individual patient and the undesirable consequences of prolonged atrial fibrillation are sufficient reasons to attempt cardioversion, should the procedure be associated with an acceptable morbidity.
Our experience with these patients confirms that procainamide is effective in converting atrial fibrillation to sinus rhythm, when used in patients without valvular heart disease or severe left ventricular insufficiency. Hypotension, however, was a common concomitant of its use. Procainamide should be considered for the elective cardioversion of cases of atrial fibrillation with a recent onset.
